Veralto Corporation (VLTO), the bio-tech company recently spinning off from Danaher, has been the subject of significant investment activity lately. Analysts suggest value investors may indulge in buying the stock, especially due to its solid start post spin-off. Veralto's Q1 and Q2 2024 earnings reportedly align with analysts' projections, with Q4 sales indicating robust year-over-year growth and free cash flow. Some stock sales from executives Honeycutt and Trivedi could spark concerns, while Aristotle Capital and Newport Trust Company have also sold their shares. However, Victory Capital Management, Primecap Management, Otter Creek Advisors, and Quantbot Technologies LP have enhanced their holdings. The VANGUARD GROUP INC has reportedly acquired a new stake in Veralto. The appointment of Vijay Sankaran to the board of directors aligns with the firm's future growth strategies. The company has managed to beat EPS revenues for Q2 2024, a positive development attracting investor attention. Over the weekend, Greater Boston gained a company on the S&P 500, while the appointment of Sameer Ralhan as CFO is expected to render much-needed financial expertise.
Veralto Corporation VLTO News Analytics from Wed, 08 Feb 2023 08:00:00 GMT to Sun, 22 Sep 2024 14:37:47 GMT -
Rating 6
- Innovation 3
- Information 8
- Rumor -2
